Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Liquidia Technologies, Inc. (LQDA : NSDQ)
 
 • Company Description   
Liquidia Technologies, Inc. is a late-stage clinical biopharmaceutical company. It focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. The company's product candidate consists of LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain which are in clinical stage. Liquidia Technologies, Inc. is based in NC, United States.

Number of Employees: 170

 
 • Price / Volume Information   
Yesterday's Closing Price: $15.26 Daily Weekly Monthly
20 Day Moving Average: 1,149,361 shares
Shares Outstanding: 85.49 (millions)
Market Capitalization: $1,304.49 (millions)
Beta: 0.24
52 Week High: $16.81
52 Week Low: $8.26
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 13.29% 7.35%
12 Week -5.80% 1.77%
Year To Date 29.76% 34.85%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
419 DAVIS DRIVE SUITE 100
-
MORRISVILLE,NC 27560
USA		 ph: 919-328-4400
fax: -		 jason.adair@liquidia.com http://www.liquidia.com
 
 • General Corporate Information   
Officers
Roger A. Jeffs - Chief Executive Officer and Director
Stephen Bloch - Chairman of the Board of Directors
Michael Kaseta - Chief Operating Officer and Chief Financial Office
Damian deGoa - Director
Katherine Rielly-Gauvin - Director

Peer Information
Liquidia Technologies, Inc. (CORR.)
Liquidia Technologies, Inc. (RSPI)
Liquidia Technologies, Inc. (CGXP)
Liquidia Technologies, Inc. (BGEN)
Liquidia Technologies, Inc. (GTBP)
Liquidia Technologies, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 53635D202
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 85.49
Most Recent Split Date: (:1)
Beta: 0.24
Market Capitalization: $1,304.49 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.42 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.46 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 35.50% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 26.23
Price/Cash Flow: -
Price / Sales: 92.23
EPS Growth
vs. Year Ago Period: 16.67%
vs. Previous Quarter: 2.17%
Sales Growth
vs. Year Ago Period: 4.98%
vs. Previous Quarter: 6.96%
ROE
03/31/25 - -177.91
12/31/24 - -161.64
09/30/24 - -163.21
ROA
03/31/25 - -60.15
12/31/24 - -63.47
09/30/24 - -67.14
Current Ratio
03/31/25 - 2.93
12/31/24 - 4.43
09/30/24 - 6.33
Quick Ratio
03/31/25 - 2.91
12/31/24 - 4.42
09/30/24 - 6.33
Operating Margin
03/31/25 - -944.10
12/31/24 - -972.38
09/30/24 - -801.89
Net Margin
03/31/25 - -903.80
12/31/24 - -931.65
09/30/24 - -765.38
Pre-Tax Margin
03/31/25 - -980.47
12/31/24 - -931.65
09/30/24 - -695.90
Book Value
03/31/25 - 0.58
12/31/24 - 0.91
09/30/24 - 1.31
Inventory Turnover
03/31/25 - 2.68
12/31/24 - 2.14
09/30/24 - 2.05
Debt-to-Equity
03/31/25 - 2.08
12/31/24 - 1.26
09/30/24 - 0.00
Debt-to-Capital
03/31/25 - 67.49
12/31/24 - 55.75
09/30/24 - 0.00
 

Powered by Zacks Investment Research ©